Pitchkit
  • Docs
  • Pricing
  • Blog
  • Tools
  • Investors
Sign inGet started
Pitchkit

Structure and stress-test your pitch with workflows built from 6+ years of VC dealflow.

Product

  • Overview
  • Pitch deck feedback
  • Pitch deck generator
  • Templates
  • Pricing

Resources

  • Learn
  • Pitch by stage
  • Slide guides
  • Docs
  • Glossary
  • Free tools

Company

  • About
  • Blog
  • Changelog
  • Contact
  • Privacy policy

Ready to pitch?

Start building your investor-ready pitch today. Free forever, no credit card required.

Start free

© 2026 Pitchkit / edgelord.tech

All systems operational
Pitchkit
Back to investor directory
Venture capital
France

Truffle Capital

Investment focus

Sectors

Biotech
Medtech
Fintech
Insurtech
AI

Investment stages

Seed
Series A
Series B
Growth

Geographic focus

Europe
France

Investment thesis

Independent European VC that creates and builds companies from inception in BioMedTech and Fintech/Insurtech. Raised over EUR 1.2B since 2001 with 13 IPOs and 17 successful exits.

Typical check size

€1M – €35M

Fund size: EUR 500M total AUM

Browse similar check sizes →

Portfolio highlights

CARMAT - total artificial heart for advanced heart failure (Euronext-listed)
Actility - IoT connectivity platform for LoRaWAN enterprise deployments
Pharnext - treatments for neurodegenerative diseases (Euronext-listed)

Contact

www.truffle.com
France

Research with AI

Learn more about Truffle Capital using AI:

Ask ChatGPTAsk Perplexity

Pitch guides

Learn what Truffle Capital and similar investors look for:

Biotech pitch guideMedtech pitch guideFintech pitch guide

More investors in France

360 CapitalAlvenAndera PartnersBlackFin Capital PartnersView all in France

Related resources

Seed fundraising guideSeed pitch deck guideSeries A fundraising guideSeries A pitch deck guideSeries B fundraising guideGrowth fundraising guide
Fundraising in France

Tips, programs, and cultural notes

More Biotech investors

AbingworthACF InvestorsAhren Innovation CapitalAlmi Invest GreenTechView all Biotech investors